Venous Thromboembolism in the Elderly

被引：3
作者：
Ali M.S. [1 ]
Czarnecka-Kujawa K. [2 ]
机构：
[1] Department of Internal Medicine, John H. Stroger, Jr. Hospital of Cook County, 1900 West Polk St, 15th Floor, Chicago, 60612, IL
[2] Division of Respirology, Division of Thoracic Surgery, Toronto General Hospital, University Health Network, University of Toronto, 585 University Ave. 9N 941, Toronto, M5G 2N2, ON
来源：
Current Geriatrics Reports | 2016年 / 5卷 / 2期
关键词：
Apixiban; Cancer; Compression stockings; Computerized tomographic angiography; Contrast-induced nephropathy; D-dimer; Dabigatran; Deep venous thrombosis; Geriatrics; Inferior vena cava filter; Low-molecular-weight heparin; Novel oral anticoagulants; Postthrombotic syndrome; Pulmonary embolism; Rivaroxaban; Thrombolysis; Ultrasonography; Unfractionated heparin; Venous thromboembolism; Warfarin; Wells Score;
D O I：
10.1007/s13670-016-0163-z
中图分类号：
学科分类号：
摘要：
Aging is a major risk factor for venous thromboembolism. Compared to the general population, the elderly have a much higher 1-year mortality from venous thromboembolism (VTE). Clinical presentation of VTE in the elderly tends to be different, with atypical symptoms being more common than in the general population. Diagnostic work-up starts with establishing a VTE pretest probability followed by D-dimer testing for patients with low pretest probability and confirmatory testing for patients with high pretest probability of VTE. The age-adjusted D-dimer cutoffs are associated with a higher specificity without compromising the test’s sensitivity. Anticoagulation is the cornerstone of VTE therapy. The use of novel oral anticoagulants is safe in elderly patients and is associated with a decreased risk of bleeding. © 2016, Springer Science+Business Media New York.
引用
收藏
页码：132 / 139
页数：7
相关论文
共 101 条
[81]  
Vogel T., Coriol V., Kaltenbach G., Kiesmann M., Berthel M., Prospective study of oral anticoagulation control in 110 very elderly hospitalized patients and of risk factors for poor control, Presse Médicale Paris Fr 1983, 37, pp. 1723-1730, (2008)
[82]  
Landefeld C.S., Goldman L., Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy, Am J Med, 87, pp. 144-152, (1989)
[83]  
Launbjerg J., Egeblad H., Heaf J., Nielsen N.H., Fugleholm A.M., Ladefoged K., Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients, J Intern Med, 229, pp. 351-355, (1991)
[84]  
Van der Meer F.J., Rosendaal F.R., Vandenbroucke J.P., Briet E., Bleeding complications in oral anticoagulant therapy. An analysis of risk factors, Arch Intern Med, 153, pp. 1557-1562, (1993)
[85]  
Sardar P., Chatterjee S., Chaudhari S., Lip G.Y.H., New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials, J Am Geriatr Soc, 62, pp. 857-864, (2014)
[86]  
Legrand M., Mateo J., Aribaud A., Ginisty S., Eftekhari P., Huy P.T.B., Et al., The use of dabigatran in elderly patients, Arch Intern Med, 171, pp. 1285-1286, (2011)
[87]  
Harper P., Young L., Merriman E., Bleeding risk with dabigatran in the frail elderly, N Engl J Med, 366, pp. 864-866, (2012)
[88]  
Wychowski M.K., Kouides P.A., Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment, Ann Pharmacother, 46, (2012)
[89]  
EINSTEIN Investigators, Bauersachs R., Berkowitz S.D., Brenner B., Buller H.R., Decousus H., Et al., Oral rivaroxaban for symptomatic venous thromboembolism, N Engl J Med, 363, pp. 2499-2510, (2010)
[90]  
EINSTEIN-PE Investigators, Buller H.R., Prins M.H., Lensin A.W.A., Decousus H., Jacobson B.F., Et al., Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, N Engl J Med, 366, pp. 1287-1297, (2012)
234567891011